Evidence map›Paper›PMID 42033449›Full record

ArticleJACC. Asia2026

Patient Characteristics and Diagnosis of Transthyretin Amyloid Cardiomyopathy in Japan: Baseline Analysis of J-COSSA.

Jin Endo, Kazumasa Tanzawa, Yasunori Sato, Hiroshi Watanabe, Seiji Takashio, Toru Kubo, Masatoshi Minamisawa, Hidekazu Tanaka, Toru Hashimoto, Hiroaki Kawano and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Jin EndoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan. Electronic address: jinendo@keio.jp.
Kazumasa TanzawaCenter of Clinical and Translational Science, St Marianna University School of Medicine, Kanagawa, Japan.
Yasunori SatoDepartment of Biostatistics, Keio University School of Medicine, Tokyo, Japan.
Hiroshi WatanabePfizer Japan Inc, Tokyo, Japan.
Seiji TakashioDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Toru KuboDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, Japan.
Masatoshi MinamisawaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Hidekazu TanakaDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Toru HashimotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hiroaki KawanoDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Konomi SakataDepartment of Clinical Engineering, Kyorin University Faculty of Health Sciences, Tokyo, Japan.
Hiromitsu KanamoriDepartment of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.
Toshihiro TsurudaCardiorenal Research Laboratory, Department of Hemo-Vascular Advanced Medicine, University of Miyazaki, Miyazaki, Japan.
Mitsuhiro FukataDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Toshiro KitagawaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Takahisa NomaDepartment of Cardiorenal Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Atsushi OkadaDepartment of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Takeshi KitaiDepartment of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Ayumu YajimaDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Mai IwatakiSecond Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hidekazu KondoDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Oita, Japan.
Yu YamadaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Shunsuke IshiiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Kanagawa, Japan.
Yasuhiro IzumiyaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Masaki IedaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Koichiro KuwaharaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Kazufumi NakamuraDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Center for Advanced Heart Failure, Okayama University Hospital, Okayama, Japan.
Nobuhiro TaharaDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Mitsuharu UedaDepartment of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yoshiki SekijimaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Hironobu NaikiDepartment of Molecular Pathology, University of Fukui, Fukui, Japan.
Kenichi TsujitaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hiroaki KitaokaDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, Japan.
Takayuki InomataDepartment of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge-scale, nationwide data for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan are limited.

objectivesThis multicenter observational, retrospective cohort study (UMIN000056734) assessed the clinical characteristics and diagnostic landscape of patients with ATTR-CM in Japan.

methodsA subcohort of patients with biopsy-proven ATTR-CM initiated on tafamidis from the J-COSSA (Japan Cohort Study of Systemic Amyloidosis) was evaluated (120 sites; April 2020 to January 2024). Baseline characteristics and investigations for the diagnosis of ATTR-CM were recorded.

resultsOverall, 1,506 patients with ATTR-CM (median [range, IQR] age, 78 [48-94, 74-82] years [n = 1,391]; men 88.9% [1,337 of 1,504]) were registered: wild-type transthyretin amyloidosis (ATTRwt), 97.9% (1,475 of 1,506); hereditary (variant) transthyretin amyloidosis (ATTRv), 2.0% (30 of 1,506); New York Heart Association (NYHA) functional class I or II, 86.6% (747 of 863); interventricular septum thickness, 15.3 ± 2.7 mm; left ventricular posterior wall thickness, 14.9 ± 2.8 mm; M protein test availability, 838 of 994 (84.3%; 30 [3.6%] tested positive); and endomyocardial biopsy, 858 (83.4% of 1,029 biopsy records). Among patients with evaluable records, technetium-99m (

conclusionsThis nationwide study clarified the clinical characteristics and diagnostic landscape of patients with biopsy-proven ATTR-CM in Japan. The results indicate that noninvasive testing is implemented for early ATTR-CM diagnosis in clinical practice and reiterate the importance of biomarkers and imaging data for early disease diagnosis.

Indexed as

(99m)Tc-labeled imagingbiopsy siteJapanesepatient characteristicsred-flag symptomstransthyretin amyloid cardiomyopathy

Identifiers

PMID42033449
PMCPMC13458800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.